Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy

被引：1

作者：

Inomata, Minehiko ^{[1
]}

Minatoyama, Shuhei ^{[1
]}

Takata, Naoki ^{[1
]}

Hayashi, Kana ^{[1
]}

Hirai, Takahiro ^{[1
]}

Seto, Zenta ^{[1
]}

Tokui, Kotaro ^{[1
]}

Taka, Chihiro ^{[1
]}

Okazawa, Seisuke ^{[1
]}

Kambara, Kenta ^{[1
]}

Imanishi, Shingo ^{[1
]}

Miwa, Toshiro ^{[1
]}

Matsuyama, Kei ^{[1
,2
]}

Hayashi, Ryuji ^{[3
]}

Matusi, Shoko ^{[1
]}

Tobe, Kazuyuki ^{[1
]}

机构：

[1] Toyama Univ Hosp, Dept Internal Med 1, Sugitani 2630, Toyama, Japan

[2] Toyama Univ Hosp, Dept Otolaryngol, Toyama, Japan

[3] Toyama Univ Hosp, Dept Med Oncol, Toyama, Japan

来源：

ANTICANCER RESEARCH | 2024年 / 44卷 / 03期

关键词：

Lung cancer; ipilimumab; nivolumab; pembrolizumab; performance status; PEMBROLIZUMAB MONOTHERAPY; ELDERLY-PATIENTS; NIVOLUMAB; EFFICACY; SAFETY;

D O I：

10.21873/anticanres.16920

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Combined therapy with immune checkpoint inhibitors plus platinum doublet chemotherapy has a survival advantage over platinum doublet chemotherapy in patients with non-small cell lung cancer. However, a variety of factors make it difficult to administer treatment with platinum doublet chemotherapy in many patients in clinical practice and there are few reports on the efficacy and safety of first-line treatments with immune checkpoint inhibitors for patients who are ineligible for platinum doublet chemotherapy. This observational study aimed to evaluate the efficacy and safety of first-line immune checkpoint inhibitor therapy for this population. Patients and Methods: We retrospectively assessed the survival and adverse events from the initiation of first-line immune checkpoint inhibitor therapy, including pembrolizumab or nivolumab plus ipilimumab in patients with non-small cell lung cancer who were ineligible for platinum doublet chemotherapy. Results: Data from 48 patients were analyzed. Seventeen patients showed a performance status (PS) of >= 2 while 16 and 15 patients were considered ineligible for platinum doublet chemotherapy because of age and comorbidities, respectively. The median (95% confidential interval, CI) progression-free survival (PFS) and overall survival (OS) of the 48 patients were 7.1 (1.7-13.7) and 31.7 (8.8-not estimated) months, respectively. The two-year PFS and OS rates (95% CI) were 30.8% (18.2%-47.2%) and 50.7% (33.7%-67.7%), respectively. In patients with a PS of >= 2, the median (95% CI) PFS and OS were 1.6 (1.2-not estimated) and 5.5 (2.3-not estimated) months, respectively. The two-year PFS and OS rates (95% CI) were 34.3% (15.8%-59.2%) and 45.3% (22.2%-70.7%), respectively. Conclusion: Patients with non-small cell lung cancer and a PS of 0-1 who were ineligible for platinum doublet chemotherapy had favorable outcome after the initiation of ICI therapy, and even in patients with a PS of >= 2, they achieved high two-year PFS and OS rates.

引用

页码：1241 / 1245

页数：5

共 14 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227 [J].

Brahmer, Julie R. ;

Lee, Jong-Seok ;

Ciuleanu, Tudor-Eliade ;

Bernabe Caro, Reyes ;

Nishio, Makoto ;

Urban, Laszlo ;

Audigier-Valette, Clarisse ;

Lupinacci, Lorena ;

Sangha, Randeep ;

Pluzanski, Adam ;

Burgers, Jacobus ;

Mahave, Mauricio ;

Ahmed, Samreen ;

Schoenfeld, Adam J. ;

Paz-Ares, Luis G. ;

Reck, Martin ;

Borghaei, Hossein ;

O'Byrne, Kenneth J. ;

Gupta, Ravi G. ;

Bushong, Judith ;

Li, Li ;

Blum, Steven I. ;

Eccles, Laura J. ;

Ramalingam, Suresh S. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) :1200-+

[3] Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study [J].

Garassino, Marina C. ;

Gadgeel, Shirish ;

Speranza, Giovanna ;

Felip, Enriqueta ;

Esteban, Emilio ;

Domine, Manuel ;

Hochmair, Maximilian J. ;

Powell, Steven F. ;

Bischoff, Helge G. ;

Peled, Nir ;

Grossi, Francesco ;

Jennens, Ross R. ;

Reck, Martin ;

Hui, Rina ;

Garon, Edward B. ;

Kurata, Takayasu ;

Gray, Jhanelle E. ;

Schwarzenberger, Paul ;

Jensen, Erin ;

Pietanza, M. Catherine ;

Rodriguez-Abreu, Delvys .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) :1992-+

[4] Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC [J].

Herbst, Roy S. ;

Giaccone, Giuseppe ;

de Marinis, Filippo ;

Reinmuth, Niels ;

Vergnenegre, Alain ;

Barrios, Carlos H. ;

Morise, Masahiro ;

Felip, Enriqueta ;

Andric, Zoran ;

Geater, Sarayut ;

Ozguroglu, Mustafa ;

Zou, Wei ;

Sandler, Alan ;

Enquist, Ida ;

Komatsubara, Kimberly ;

Deng, Yu ;

Kuriki, Hiroshi ;

Wen, Xiaohui ;

McCleland, Mark ;

Mocci, Simonetta ;

Jassem, Jacek ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) :1328-1339

[5] Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer [J].

Imai, Hisao ;

Wasamoto, Satoshi ;

Yamaguchi, Ou ;

Suzuki, Kensuke ;

Sugiyama, Tomohide ;

Uchino, Junji ;

Minemura, Hiroyuki ;

Osaki, Takashi ;

Ishii, Hisashi ;

Umeda, Yukihiro ;

Mori, Keita ;

Kotake, Mie ;

Kagamu, Hiroshi ;

Morozumi, Nobutoshi ;

Taniguchi, Hirokazu ;

Kasai, Takashi ;

Minato, Koichi ;

Kaira, Kyoichi .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (02) :457-466

[6] Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors [J].

Leaf, Rebecca Karp ;

Ferreri, Christopher ;

Rangachari, Deepa ;

Mier, James ;

Witteles, Wesley ;

Ansstas, George ;

Anagnostou, Theodora ;

Zubiri, Leyre ;

Piotrowska, Zofia ;

Oo, Thein H. ;

Iberri, David ;

Yarchoan, Mark ;

Salama, April K. S. ;

Johnson, Douglas B. ;

Leavitt, Andrew D. ;

Rahma, Osama E. ;

Reynolds, Kerry L. ;

Leaf, David E. .

AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (05) :563-574

[7] Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial [J].

Middleton, Gary ;

Brock, Kristian ;

Savage, Joshua ;

Mant, Rhys ;

Summers, Yvonne ;

Connibear, John ;

Shah, Riyaz ;

Ottensmeier, Christian ;

Shaw, Paul ;

Lee, Siow-Ming ;

Popat, Sanjay ;

Barrie, Colin ;

Barone, Gloria ;

Billingham, Lucinda .

LANCET RESPIRATORY MEDICINE, 2020, 8 (09) :895-904

[8] Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data [J].

Nakahama, Kenji ;

Izumi, Motohiro ;

Yoshimoto, Naoki ;

Fukui, Mitsuru ;

Sugimoto, Akira ;

Nagamine, Hiroaki ;

Ogawa, Koichi ;

Sawa, Kenji ;

Tani, Yoko ;

Kaneda, Hiroyasu ;

Mitsuoka, Shigeki ;

Watanabe, Tetsuya ;

Asai, Kazuhisa ;

Kawaguchi, Tomoya .

ANTICANCER RESEARCH, 2023, 43 (05) :2185-2197

[9] Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies [J].

Nosaki, Kaname ;

Saka, Hideo ;

Hosomi, Yukio ;

Baas, Paul ;

de Castro, Gilberto, Jr. ;

Reck, Martin ;

Wu, Yi-Long ;

Brahmer, Julie R. ;

Felip, Enriqueta ;

Sawada, Takeshi ;

Noguchi, Kazuo ;

Han, Shi Rong ;

Piperdi, Bilal ;

Kush, Debra A. ;

Lopes, Gilberto .

LUNG CANCER, 2019, 135 :188-195

[10] Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer [J].

Oya, Yuko ;

Yoshida, Tatsuya ;

Kuroda, Hiroaki ;

Mikubo, Masashi ;

Kondo, Chiaki ;

Shimizu, Junichi ;

Horio, Yoshitsugu ;

Sakao, Yukinori ;

Hida, Toyoaki ;

Yatabe, Yasushi .

ONCOTARGET, 2017, 8 (61) :103117-103128

← 1 2 →